Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Ad.TRAIL
- Development stage
- Unknown
- Lead developer
- University of Iowa
- Modality
- Gene Addition/Replacement → Gene Therapies, Gene Editing → Gene Therapies, Gene Silencing → Gene Therapies
- Administration
- Intratumoral
01
Overview
Ad.TRAIL (also referred to as Ad5-TRAIL or Ad-TRAIL) is a replication-deficient recombinant adenoviral gene therapy vector (specifically adenovirus serotype 5) encoding the human tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) cDNA. Developed by researchers at the University of Iowa, Ad.TRAIL is designed to deliver the TRAIL gene directly into tumor cells, leading to the expression of membrane-bound TRAIL protein on the cell surface. This protein selectively binds to death receptors 4 and 5 (DR4 and DR5) on cancer cells, triggering the extrinsic apoptotic pathway and inducing tumor cell death while sparing normal tissues. Ad.TRAIL has been evaluated in a Phase I clinical trial for the treatment of locally-confined prostate cancer and has shown potential in preclinical studies for other malignancies, including renal cell carcinoma, pancreatic cancer, and non-small cell lung cancer.
- Other names
- adenovirus-encoded TRAILadenovirus-mediated TRAILrecombinant adenovirus encoding TRAIL
02
Targets
OPG (Osteoprotegerin)CXADR (Coxsackievirus and adenovirus receptor)TNFRSF10D (TRAIL receptor 4)TNFRSF10B (DR5)TNFRSF10CTNFRSF10A (Death receptor 4)
Beyond the preview
Go deeper on Ad.TRAIL.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Ad.TRAIL.